Skip to main content
Top
Published in: Supportive Care in Cancer 1/2007

01-01-2007 | Supportive Care International

Clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia Scale

Authors: Maya Kurita, Kojiro Shimozuma, Satoshi Morita, Yuki Fujiki, Kenichi Ishizawa, Hisae Eguchi, Yuko Saito, Nobuko Ushirozawa, Izumi Wasada, Yasuo Ohashi, Kenji Eguchi

Published in: Supportive Care in Cancer | Issue 1/2007

Login to get access

Abstract

Goals of work

The purpose of this study was to reveal the clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia scale (FACT-An) in relation to hemoglobin level. We also analyzed patients’ scores for the related FACT-General scale (FACT-G), the FACT Anemia subscale, and the FACT Trial Outcome Index-Anemia scale (FACT TOI-An) to determine which was the most sensitive to anemia measurements.

Materials and methods

Throughout Japan, we recruited 227 patients (mean±SD, 59±12.1 years old) diagnosed with a variety of cancers. We correlated the severity of anemia, as measured by hemoglobin levels, to scores on the FACT-An and on the other scales at baseline and at 3 months.

Main results

The questionnaire completion rate was more than 98% at both time points. The FACT-An had high internal consistency (Cronbach’s alpha coefficient >0.8). FACT-An scores were significantly and positively correlated with hemoglobin levels both at baseline (r=0.24; 95% CI=0.12 to 0.36; n=225) and at 3 months (r=0.24; 95% CI=0.10 to 0.36; n=204). FACT-G, FACT Anemia subscale, and FACT TOI-An scores also successfully discriminated between patients with lower (Hb <11.0 g/dl) and higher (Hb ≥11.0 g/dl) hemoglobin levels. Moreover, the changes of these FACT scores over 3-months could discriminate changes in hemoglobin level.

Conclusion

The Japanese version of the FACT-An has higher clinical validity and can be used to appropriately assess health-related quality of life among Japanese cancer patients with anemia.
Literature
1.
go back to reference Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(3 Suppl 2):13–19PubMed Cella D (1997) The Functional Assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34(3 Suppl 2):13–19PubMed
2.
go back to reference Cella DF, Tulsky DS, Gray G, Sarafian B et al (1993) The Functional Assessment Of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed Cella DF, Tulsky DS, Gray G, Sarafian B et al (1993) The Functional Assessment Of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 11(3):570–579PubMed
3.
go back to reference Cella DF, Bonmi AE, Lloyd SR et al (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12(3):199–220PubMedCrossRef Cella DF, Bonmi AE, Lloyd SR et al (1995) Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12(3):199–220PubMedCrossRef
4.
go back to reference Cella D, Zagari MJ, Vandoros C et al (2003) Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21(2):366–373PubMedCrossRef Cella D, Zagari MJ, Vandoros C et al (2003) Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 21(2):366–373PubMedCrossRef
5.
go back to reference Crawford J, Cella D, Cleeland CS et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95(4):888–895PubMedCrossRef Crawford J, Cella D, Cleeland CS et al (2002) Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 95(4):888–895PubMedCrossRef
6.
go back to reference Fumimoto H, Kobayashi K, Chang CH et al (2001) Cross-cultural validation of an international questionnaire, the general measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res 10(8):701–709PubMedCrossRef Fumimoto H, Kobayashi K, Chang CH et al (2001) Cross-cultural validation of an international questionnaire, the general measure of the Functional Assessment of Cancer Therapy scale (FACT-G), for Japanese. Qual Life Res 10(8):701–709PubMedCrossRef
7.
go back to reference Littlewood TJ, Bajetta E, Nortier W et al (2001) Effects of epoetin alfa on hematologic parameters and QOL in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 19(11):2865–2874PubMed Littlewood TJ, Bajetta E, Nortier W et al (2001) Effects of epoetin alfa on hematologic parameters and QOL in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double blind, placebo-controlled trial. J Clin Oncol 19(11):2865–2874PubMed
8.
go back to reference Noguchi W, Ohno T, Morita S et al (2004) Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp) for Japanese patients with cancer. Support Care Cancer 12(4):240–245PubMedCrossRef Noguchi W, Ohno T, Morita S et al (2004) Reliability and validity of the Functional Assessment of Chronic Illness Therapy-Spiritual (FACIT-Sp) for Japanese patients with cancer. Support Care Cancer 12(4):240–245PubMedCrossRef
9.
go back to reference Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23(12):2606–2617PubMedCrossRef Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23(12):2606–2617PubMedCrossRef
10.
go back to reference Yoshimura A, Kobayashi K, Fumimoto H et al (2004) Cross-cultural validation of the Japanese Functional Assessment of Cancer Therapy-Anemia (FACT-An). J Nippon Med Sch Nihon Ika Daigaku Zasshi 71(5):314–322 Yoshimura A, Kobayashi K, Fumimoto H et al (2004) Cross-cultural validation of the Japanese Functional Assessment of Cancer Therapy-Anemia (FACT-An). J Nippon Med Sch Nihon Ika Daigaku Zasshi 71(5):314–322
Metadata
Title
Clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia Scale
Authors
Maya Kurita
Kojiro Shimozuma
Satoshi Morita
Yuki Fujiki
Kenichi Ishizawa
Hisae Eguchi
Yuko Saito
Nobuko Ushirozawa
Izumi Wasada
Yasuo Ohashi
Kenji Eguchi
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 1/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0138-2

Other articles of this Issue 1/2007

Supportive Care in Cancer 1/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine